Reckitt Benckiser Group plc (OTCMKTS:RBGLY - Get Free Report)'s stock price passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $12.75 and traded as low as $12.67. Reckitt Benckiser Group shares last traded at $12.76, with a volume of 434,805 shares trading hands.
Analysts Set New Price Targets
A number of analysts have weighed in on the company. Barclays cut Reckitt Benckiser Group from an "overweight" rating to an "equal weight" rating in a research report on Tuesday, February 4th. Royal Bank of Canada reiterated an "outperform" rating on shares of Reckitt Benckiser Group in a research report on Friday, March 7th. Three research analysts have rated the stock with a hold rating, two have given a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Buy".
Read Our Latest Analysis on RBGLY
Reckitt Benckiser Group Trading Up 0.5%
The firm has a fifty day moving average price of $13.06 and a 200 day moving average price of $12.75. The company has a debt-to-equity ratio of 0.97, a quick ratio of 0.47 and a current ratio of 0.69.
Reckitt Benckiser Group Increases Dividend
The firm also recently announced a dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 11th will be issued a dividend of $0.2909 per share. The ex-dividend date is Friday, April 11th. This is a boost from Reckitt Benckiser Group's previous dividend of $0.19.
About Reckitt Benckiser Group
(
Get Free Report)
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.
Featured Articles
Before you consider Reckitt Benckiser Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Reckitt Benckiser Group wasn't on the list.
While Reckitt Benckiser Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
